Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

967
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
967
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

170
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
170
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

582
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
582
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

217
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
217
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

180
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
180
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

146
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
146

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Killip class at presentation and immediate versus staged multivessel PCI in patients with STEMI.

Scientific reports·2026
Same author

Impact of renal dysfunction on immediate versus staged revascularization of non-culprit lesions in patients with ST segment elevation myocardial infarction: a pre-specified subgroup analysis of the randomized MULTISTARS AMI trial.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same author

Impact of diabetes on outcomes of patients with ST-segment elevation myocardial infarction and multivessel coronary artery disease undergoing percutaneous coronary intervention.

Clinical research in cardiology : official journal of the German Cardiac Society·2025
Same author

Impact of ticagrelor with or without aspirin on total and recurrent bleeding and ischaemic events after percutaneous coronary intervention: a sub-study of the TWILIGHT trial.

European heart journal. Cardiovascular pharmacotherapy·2024
Same author

Incidence and pattern of urgent revascularization in acute coronary syndromes treated with ticagrelor or prasugrel.

Clinical research in cardiology : official journal of the German Cardiac Society·2024
Same author

Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention.

JACC. Cardiovascular interventions·2023

Related Experiment Video

Updated: Dec 25, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.4K

Ticagrelor With or Without Aspirin After Complex PCI.

George Dangas1, Usman Baber1, Samin Sharma1

  • 1The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

Journal of the American College of Cardiology
|April 3, 2020
PubMed
Summary
This summary is machine-generated.

Ticagrelor monotherapy significantly reduced bleeding complications in patients with complex percutaneous coronary intervention (PCI). This approach maintained similar ischemic event rates compared to dual antiplatelet therapy.

Keywords:
aspirinbleedingcomplex PCIdual antiplatelet therapyticagrelor monotherapy

More Related Videos

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.7K
Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

459

Related Experiment Videos

Last Updated: Dec 25, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.4K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.7K
Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

459

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Pharmacology

Background:

  • The optimal antiplatelet strategy following complex percutaneous coronary intervention (PCI) remains under investigation.
  • Evaluating ticagrelor monotherapy's safety and efficacy in reducing bleeding without compromising ischemic outcomes is crucial.

Purpose of the Study:

  • To assess the impact of ticagrelor monotherapy versus ticagrelor plus aspirin on bleeding and ischemic events in patients undergoing complex PCI.
  • To analyze data from the randomized, double-blind, placebo-controlled TWILIGHT trial.

Main Methods:

  • Patients completing 3 months of ticagrelor plus aspirin were randomized to 1 year of ticagrelor monotherapy or continued dual therapy.
  • Complex PCI included criteria such as multiple vessels/lesions, long stent length, or use of atherectomy.
  • Bleeding Academic Research Consortium (BARC) types 2, 3, 5 and ischemic events were primary endpoints.

Main Results:

  • Ticagrelor monotherapy significantly lowered rates of BARC types 2, 3, or 5 bleeding (4.2% vs. 7.7%) and BARC types 3 or 5 bleeding (1.1% vs. 2.6%) compared to ticagrelor plus aspirin.
  • No significant differences were observed in the rates of death, myocardial infarction, stroke, or stent thrombosis between the groups.
  • These findings were specifically analyzed within a subgroup of 2,342 patients who underwent complex PCI.

Conclusions:

  • Continuation of ticagrelor monotherapy after an initial period of dual therapy is associated with reduced bleeding incidence in patients with complex PCI.
  • Ticagrelor monotherapy did not increase the risk of ischemic events compared to continuing ticagrelor plus aspirin.
  • The TWILIGHT trial provides evidence supporting ticagrelor monotherapy as a safer alternative for selected patients post-complex PCI.